trending Market Intelligence /marketintelligence/en/news-insights/trending/fSry0i7Wy1PF71VVXfSgVg2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Iterum's antibiotic sulopenem narrowly misses goal of late-stage study

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Iterum's antibiotic sulopenem narrowly misses goal of late-stage study

Iterum Therapeutics PLC's antibiotic sulopenem did not perform better than Merck & Co. Inc.'s Invanz in treating complicated intra-abdominal infections in a late-stage study.

The phase 3 study, dubbed Sure 3, enrolled 668 patients with different intra-abdominal infections. These complicated infections extend from a gastrointestinal source, such as the appendix or the colon, into the peritoneal space and can be associated with abscess formation.

According to the Irish pharmaceutical company, sulopenem narrowly missed the study's main goal, producing a clinical response in 85.5% of patients by day 28 compared to 90.2% for Invanz, or ertapenem. Drug-related adverse events were reported in 6.0% and 5.1% of patients on sulopenem and Invanz, respectively, with diarrhea being the most common. Treatment was discontinued in 1.5% of patients on sulopenem compared to 2.1% on Invanz.

The U.S. Food and Drug Administration previously granted sulopenem special protocol agreements, qualified infectious disease product status and fast track designation for oral and IV sulopenem for the treatment of community-acquired bacterial pneumonia, acute bacterial prostatitis, gonococcal urethritis and pelvic inflammatory disease.

Iterum's stock was down by 38.14% to $3 as of 5:21 p.m. ET.